Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues.
Nicotinamide
Placenta
Preeclampsia
Soluble endoglin
sFlt-1
Journal
Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
27
10
2020
revised:
29
03
2021
accepted:
13
04
2021
pubmed:
7
5
2021
medline:
27
1
2022
entrez:
6
5
2021
Statut:
ppublish
Résumé
Preeclampsia is a serious pregnancy complication associated with elevated antiangiogenic markers and endothelial dysfunction. Recently nicotinamide (vitamin B3) was shown to reduce high blood pressure and proteinuria in mice models of the disease. Using primary human pregnancy tissue we show nicotinamide did not change antiangiogenic factor secretion including soluble fms-like tyrosine kinase 1 or soluble endoglin from primary cytotrophoblasts and placental explants. Furthermore, it did not reverse markers of endothelial dysfunction. Therefore, we did not demonstrate an effect of nicotinamide on reducing markers of preeclampsia from primary human placental tissues and vascular cells.
Identifiants
pubmed: 33957335
pii: S0143-4004(21)00122-3
doi: 10.1016/j.placenta.2021.04.007
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-31Informations de copyright
Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.